# NIVOREN (NCT03013335)

> Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

No report yet. It can be ordered.

- Drugs tested: nivolumab
- Indication: metastatic clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03013335
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: UNICANCER
- Conditions: Metastatic Renal Cell Carcinoma
- Interventions: Nivolumab
- Enrollment: 730
- Primary outcome: Incidence for high-grade (Grade3-4-5) adverse reactions of interest

## Indexed commentary on NIVOREN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 14 posts on X
- 2 YouTube videos

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nivoren-nct03013335

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03013335", "email": "<work email>"}; the inbox owner confirms by the emailed link.